Breaks Categories: News

MondaySep 26, 2016 11:03 am

Actua Corp. (ACTA) Reaches Agreement to Sell GovDelivery for $153 Million in Cash

Actua Corp. (NASDAQ: ACTA) signed a definitive agreement to sell GovDelivery to an investor group led by Vista Equity Partners for $153 million in cash, subject to certain adjustments, including working capital, cash, debt and other items. The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2016. Actua’s stated intentions are to use the proceeds to enhance shareholder value while staying focused on building its cloud businesses and repurchasing shares. To view the full press release, visit: http://nnw.fm/6Ecan About Actua Corp. Actua is a multi-vertical cloud company bringing the power of…

Continue Reading

MondaySep 26, 2016 10:56 am

Summit Therapeutics plc (SMMT) Receives Fast Track Designation for Duchenne Muscular Dystrophy

Summit Therapeutics plc (NASDAQ: SMMT) was pleased to announce today that the US Food and Drug Administration (‘FDA’) granted Fast Track designation for ezutromid in the treatment of Duchenne Muscular Dystrophy (DMD). Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD. Advantages of this designation include opportunities for frequent interactions with the FDA during all aspects of development, submission of a New Drug Application (‘NDA’) on a rolling basis, and eligibility for accelerated approval and priority review. To view the full press release, visit: http://nnw.fm/t43jX About Summit…

Continue Reading

MondaySep 26, 2016 10:56 am

Lipocine, Inc. (LPCN) Announces Phase 2b Study Results for LPCN 1111

Lipocine, Inc. (NASDAQ: LPCN) reported positive top-line results from a Phase 2b clinical study its novel oral testosterone replacement therapy ("TRT") product candidate. Named LPCN 1111, this prodrug is believed to have met the primary objectives of demonstrating the Phase 3 Dose as well as safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males. Notably, the prodrug was well tolerated with no drug-related severe or serious adverse events reported. To view the full press release, visit: http://nnw.fm/xY8YL About Lipocine Lipocine is a specialty pharmaceutical company focused on developing innovative…

Continue Reading

MondaySep 26, 2016 10:56 am

Array BioPharma, Inc. (ARRY) Reports Top-Line Results from Phase 3 Study

Array BioPharma, Inc. (NASDAQ: ARRY) jointly announced with Pierre Fabre the results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, meaningfully improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone. To view the full press release, visit: http://nnw.fm/iV5kO About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small…

Continue Reading

MondaySep 26, 2016 10:55 am

Limelight Networks, Inc. (LLNW) Selected to Deliver Video Services to Millions of Subscribers

Limelight Networks, Inc. (NASDAQ: LLNW) announced that GoChina TV selected the company to provide over-the-top (OTT) video service to millions of subscribers worldwide. GoChina TV CEO indicated that the Limelight content delivery network (CDN) is superior to other CDNs tried in the past. Excellent local technical support was also a key factor. GoChina TV will benefit greatly from having a reliable and intuitive platform from Limelight that can scale as needed to accommodate an increasing number of subscribers and high quality content. To view the full press release, visit: http://nnw.fm/GDj5A About Limelight Networks Limelight is a top tier content delivery…

Continue Reading

FridaySep 23, 2016 1:27 pm

Cowen Group, Inc.’s (COWN) Prime Services Division Wins another Hedgeweek Award

Cowen Group (NASDAQ: COWN) this morning announced that its Cowen Prime Services LLC division was named Best North American Prime Broker at the 2016 Hedgeweek USA Awards. The award is based on a peer review system with the top performer of each category selected by Hedgeweek’s audience of institutional and high net worth investors, hedge fund managers and other industry professionals at fund administrators, prime brokers, law firms, custodians and advisers. This the second consecutive year, and the third in four, that Cowen Prime has received this award. Additionally, Cowen Prime earlier this year was named “Best Global Prime Broker”…

Continue Reading

FridaySep 23, 2016 1:24 pm

Aehr Test Systems (AEHR) Announces Private Placement, Posts Preliminary Q1 2017 Financial Results

Aehr Test Systems (NASDAQ: AEHR) has signed a definitive purchase agreement for the sale of approximately $5.9 million in shares of its common stock (priced at $2.15 per share) in a private placement transaction with certain institutional and accredited investors. The supplier of semiconductor test and burn-in equipment plans to use the net proceeds for working capital and general corporate purposes. Aehr also announced preliminary financial results for Q1 of fiscal 2017, expecting a GAAP net loss between $800,000 and $900,000 on revenue of $5.3 million, compared to a net loss of $3.1 million on revenue of $1.6 million in Q4…

Continue Reading

FridaySep 23, 2016 1:22 pm

BioLineRx (BLRX) In-Licenses Novel Treatment for Liver Failure Conditions

BioLineRx Ltd. (NASDAQ/TASE: BLRX) this morning said it has entered into an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, regarding the in-licensing of BL-1220 for the treatment of liver pathologies. BL-1220 marks BioLineRx’s second project in-licensed under its collaboration with Novartis Pharma AG (NYSE: NVS) for the screening and development of novel drug candidates.  "In August this year, we in-licensed the first compound under our multi-year strategic partnership with Novartis … Today, we are pleased to announce the second compound under the Novartis collaboration…

Continue Reading

FridaySep 23, 2016 1:19 pm

Laguna Blends, Inc. (LAG) (LAGBF) (LB6A.F) Joins Canadian Securities Exchange Composite Index

Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) this morning announced its inclusion to the CSE Composite index, reflecting the network marketing company’s aggressive expansion strategy. "Inclusion in the CSE Composite index is another indicator Laguna continues to deliver shareholder value through its strategic growth strategy. Laguna has positioned itself to be a dominant player in the distribution and marketing of unique hemp and CBD related products around the world," Bryan Loree, CFO of Laguna Blends, stated in the news release. Laguna Blends uses a network of independent affiliates to market its hemp-based functional beverages, and is exclusively licensed…

Continue Reading

ThursdaySep 22, 2016 2:09 pm

Terra Tech Corp.’s (TRTC) Edible Garden Begins Shipping Herb Line to Latest Customer

Terra Tech (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, this morning announced that its Edible Garden subsidiary has commenced shipping of its line of 4-inch potted living herbs to nationwide supermarket chain Wegmans Food Markets, Inc. Edible Garden is a retail seller of locally grown hydroponic produce, herbs and floral products. Its living potted herbs are USDA-certified organic and without contaminants, pesticides and GMOs. The company says that since Q2 2016 it has more than tripled production of its herb line in response to supermarket demand and increasing popularity among consumers. “As a result of the popularity of this…

Continue Reading